Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spyridon Siafis

Showing results (1-10 of 109) with videos related to

Pageof 11
Sort By:
British Journal of Clinical Pharmacology|June 29, 2018
Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic studySpyridon Siafis, Georgios Papazisis
Current Clinical Pharmacology|November 3, 2018
The Added Value of Liquid Antipsychotics: The Case of QuetiapineGeorgios Papazisis, Spyridon Siafis
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 4, 2023
Clinician- versus caregiver-rated scales as outcome measures of repetitive-restricted behaviors in clinical trials of autism: A systematic review and meta-analysisSpyridon Siafis, Stefan Leucht
Behavioural Brain Research|February 13, 2021
Safety of antipsychotic drugs: A systematic review of disproportionality analysis studiesDainora Cepaityte, Spyridon Siafis, Georgios Papazisis
Substance Abuse : Research and Treatment|September 29, 2018
Nonmedical Use of Prescription Drugs among Medical Students and the Relationship With Illicit Drug, Tobacco, and Alcohol UseGeorgios Papazisis, Ioannis Tsakiridis, Spyridon Siafis
The American Journal of Case Reports|April 8, 2018
Tachyphylaxis to the Sedative Action of MirtazapineGeorgios Papazisis, Spyridon Siafis, Dimitrios Tzachanis
Lancet (London, England)|September 26, 2022
Maintenance antipsychotic trials and the effect of withdrawal - Authors' replyJohannes Schneider-Thoma, Spyridon Siafis, Stefan Leucht
JAMA Psychiatry|November 24, 2021
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia-ReplyStefan Leucht, Spyridon Siafis, John M Davis
British Journal of Clinical Pharmacology|May 17, 2021
Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System databaseVasileios-Periklis Stamatellos, Spyridon Siafis, Georgios Papazisis
Psychological Medicine|January 9, 2020
Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-NomenclatureSpyridon Siafis, John M Davis, Stefan Leucht
Pageof 11

Showing results (1-10 of 109) with videos related to

Sort By:
Pageof 11
British Journal of Clinical Pharmacology|June 29, 2018
Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic studySpyridon Siafis, Georgios Papazisis
Current Clinical Pharmacology|November 3, 2018
The Added Value of Liquid Antipsychotics: The Case of QuetiapineGeorgios Papazisis, Spyridon Siafis
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 4, 2023
Clinician- versus caregiver-rated scales as outcome measures of repetitive-restricted behaviors in clinical trials of autism: A systematic review and meta-analysisSpyridon Siafis, Stefan Leucht
Behavioural Brain Research|February 13, 2021
Safety of antipsychotic drugs: A systematic review of disproportionality analysis studiesDainora Cepaityte, Spyridon Siafis, Georgios Papazisis
Substance Abuse : Research and Treatment|September 29, 2018
Nonmedical Use of Prescription Drugs among Medical Students and the Relationship With Illicit Drug, Tobacco, and Alcohol UseGeorgios Papazisis, Ioannis Tsakiridis, Spyridon Siafis
The American Journal of Case Reports|April 8, 2018
Tachyphylaxis to the Sedative Action of MirtazapineGeorgios Papazisis, Spyridon Siafis, Dimitrios Tzachanis
Lancet (London, England)|September 26, 2022
Maintenance antipsychotic trials and the effect of withdrawal - Authors' replyJohannes Schneider-Thoma, Spyridon Siafis, Stefan Leucht
JAMA Psychiatry|November 24, 2021
Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia-ReplyStefan Leucht, Spyridon Siafis, John M Davis
British Journal of Clinical Pharmacology|May 17, 2021
Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System databaseVasileios-Periklis Stamatellos, Spyridon Siafis, Georgios Papazisis
Psychological Medicine|January 9, 2020
Antipsychotic drugs: from 'major tranquilizers' to Neuroscience-based-NomenclatureSpyridon Siafis, John M Davis, Stefan Leucht
Pageof 11